Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue$3.56M$3.56M+13.6% vs Q3 2024 Net Income-$928.00K-$928.00KN/M vs Q3 2024 EPS Diluted-$0.63-$0.63N/M vs Q3 2024 Gross Profit$1,270,000−13.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived$565,000N/M Free Cash Flowderived$563,000N/M Margins · derivedGross margin35.6%−10.9 pt vs Q3 2024
Operating margin-28.9%−2.0 pt vs Q3 2024
Net margin-26.0%+1.6 pt vs Q3 2024
ended Dec 31, 2024 · filed Feb 5, 2025 · 36 d after period end